series-b
Stage
2013
Founded
1
Investors
About
TILT Biotherapeutics develops intravenously delivered oncolytic adenoviral immunotherapies armed with cytokines TNF and IL-2 to stimulate anti-tumor T-cell responses for the treatment of solid tumors.
Explore TILT Biotherapeutics Oy's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.